1. Scrip
  2. >>Therapy Areas

EU accepts filing for monthly Abilify for schizophrenia maintenance

 
• By Ian Haydock

The European Medicines Agency has formally accepted a marketing authorization application for a once-monthly intramuscular depot formulation of Otsuka Pharmaceutical's atypical antipsychotic Abilify (aripiprazole), in line with expectations of a filing by the end of the year.

The European Medicines Agency has formally accepted a marketing authorization application for a once-monthly intramuscular depot formulation of Otsuka Pharmaceutical's atypical antipsychotic Abilify (aripiprazole), in line with expectations of a filing by the end of the year.

The Japanese firm and its partner Lundbeck are seeking approval of the long-acting formulation of the dopamine D2 partial agonist...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Neurological

More from Therapeutic Category

Biogen Edges Closer To Growth On Strong Q2

 
• By Jessica Merrill

Sales of Leqembi, Zurzuvae and Skyclarys contributed to Biogen’s sales and earnings guidance raise, positioning the company closer to potential growth.

Amvuttra Makes Strong ATTR-CM Showing As Alnylam Prepares For Global Launches

 
• By Alaric DeArment

In an interview, chief commercial officer Tolga Tanguler gave some ideas of what to expect as the company prepares to launch the drug for ATTR-CM in Europe.

Argenx Powers Ahead With Vyvgart’s Prefilled Syringe Launch

 
• By Andrew McConaghie

The Netherlands-headquartered company is enjoying huge success with Vyvgart in two autoimmune conditions, with a new prefilled syringe version reaching more patient groups.